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Interobserver variation in CD30 immunohistochemistry interpretation; consequences for
patient selection for targeted treatment
Aims: CD30 immunohistochemistry (IHC) in malig-
nant lymphoma is used for selection of patients in clini-
cal trials using brentuximab vedotin, an antibody drug-
conjugate targeting the CD30 molecule. For reliable
implementation in daily practice and meaningful selec-
tion of patients for clinical trials, information on techni-
cal variation and interobserver reproducibility of CD30
immunohistochemistry (IHC) staining is required.
Methods and results: We conducted a three-round repro-
ducibility assessment of CD30 scoring for categorised fre-
quency and intensity, including a technical validation, a
‘live polling’ pre- and post-instruction scoring round and a
web-based round including individual scoring with addi-
tional IHC information to mimic daily diagnostic practice.
Agreement in all three scoring rounds was poor to fair
(j = 0.12–0.35 for CD30-positive tumour cell percentage
and j = 0.16–0.41 for staining intensity), even when
allowing for one category of freedom in percentage of
tumour cell positivity (j = 0.30–0.61). The first round
with CD30 staining performed in five independent labora-
tories showed objective differences in staining intensity. In
the second round, approximately half the pathologists
changed their opinion on CD30 frequency after a discus-
sion on potential pitfalls, highlighting hesitancy in deci-
sion-making. Using fictional cut-off points for percentage of
tumour cell positivity, agreement was still suboptimal
(j = 0.35–0.60).
Conclusions: Lack of agreement in cases with
heterogeneous expression is shown to influence
patient eligibility for treatment with brentuximab
vedotin, both in clinical practice and within the con-
text of clinical trials, and limits the potential predic-
tive value of the relative frequency of CD30-positive
neoplastic cells for clinical response.
Keywords: CD30, immunohistochemistry, interobserver variation, malignant lymphoma
Introduction
Immunohistochemistry (IHC) characterisation is an
integral part of daily pathology practice for classifying
and subtyping various malignancies, including malig-
nant lymphomas. In recent years, targeted therapies
related to specific proteins expressed on tumour cells
have prompted the use of IHC for the detection or
measurement of these specific molecules as predictive
markers for treatment outcome. Examples include
human epidermal growth factor receptor 2 (HER2)
assessment as a predictive marker for decision-
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making in breast cancer treatment with targeted
therapy against HER2,1 programmed cell death
ligand 1 (PDL-1) staining on tumour cells and
tumour-associated histiocytes in relation to pro-
grammed cell death 1 (PD-1) inhibitory treatment in
melanoma patients2 and, increasingly, selection of
patients with diffuse large B cell lymphoma (DLBCL)
for treatment choices within and outside clinical trials
based on IHC algorithms for cell-of-origin classifica-
tion.3
In recent years, CD30 has gained attention as a
molecule of interest for targeted therapy of haemato-
logical malignancies. CD30 is a type I transmembrane
protein with six cysteine-rich pseudo-repeat motifs in
its extracellular domain, and contains a cytoplasmic
tail with several tumour necrosis factor receptor-bind-
ing sequences that are able to activate nuclear factor
kappa B (NF-jB) and extracellular signal-regulated
kinase signalling pathways.4 CD30 can be targeted
specifically by brentuximab vedotin,5 a CD30 anti-
body drug-conjugate, that has shown high efficacy in
classical Hodgkin lymphoma (CHL) and anaplastic
large cell lymphoma (ALCL), malignant lymphomas
with often strong and homogeneous IHC expression
of CD30. Other lymphoma classes, such as diffuse
large B cell lymphoma (DLBCL) and various T cell
lymphoma subtypes [especially extranodal natural
killer (NK)/T cell lymphomas and enteropathy-asso-
ciated T cell lymphomas (EATL)], may express CD30,
albeit with heterogeneous staining intensity and per-
centage of positive tumour cells, and currently the
efficacy of treatment with brentuximab vedotin is
being explored actively in these lymphoma types.6,7
However, there is no consensus on CD30 cut-points
or the staining pattern that should be observed, and
widely variable criteria are used.8,9
These developments imply that the role of the
pathologist to support selection of patients for treat-
ment will increase further in this field. Building upon
the experience with major reproducibility issues and
variable cut-off point definitions for predictive IHC
markers, both in solid tumours10,11 and lymphoma,12
similar challenges may be expected for CD30 testing.
Before meaningful implementation of predictive scor-
ing for CD30 in daily practice, this aspect should be
evaluated, especially as variations will probably influ-
ence eligibility for inclusion in clinical trials and may
preclude meaningful correlative studies. Therefore, we
performed a three-round formal validation study
including aspects of technical reproducibility/interlab-
oratory variability, interobserver variability and
learning effects.
Materials and methods
T I S S U E M I C R O A R R A Y ( T M A )
TMAs were constructed using 20 archival formalin-
fixed and paraffin-embedded (FFPE) patient samples
originating from one pathology laboratory of various
lymphoid malignancies to cover various staining
intensities and positive tumour cell frequencies for
CD30 and known pitfalls, including 12 cases of
DLBCL, three cases of EATL and one case each of
mediastinal grey zone lymphoma, adult T cell lym-
phoma/leukaemia (ATLL), peripheral T cell lym-
phoma, not otherwise specified (PTCL-NOS), and
ALK1-negative ALCL. Two representative 1.0-mm
cores were processed using standard procedures.13
Five-micrometre sections were cut and sent to five
pathology laboratories in The Netherlands for stain-
ing with CD30 antibodies using local protocols for
routine diagnostic procedures.
I H C I N T E R P R E T A T I O N
In all assessments, the percentage of CD30-positive
neoplastic cells and the intensity of staining were esti-
mated visually. Positive tumour cells were scored in
percentage classes: no expression, > 0–2%, 3–10%,
11–20%, 21–30%, 31–50% and > 50%. Staining
intensity was scored as no expression, heteroge-
neously negative–weak, uniformly weak, heteroge-
neously weak–strong and uniformly strong.
For round 1 of technical validation and IHC inter-
pretation, each core of the TMA was assessed by the
local pathologist of the laboratory that performed the
staining procedure (n = 5).
Round 2 was performed during a national work-
shop on CD30 as a therapeutic target in haemato-
logical malignancies, in which 25 medical
professionals, including (haemato)pathologists, hae-
mato-oncologists and dermatologists, participated in
a live polling system for six cases using on-screen
photographs of CD30 staining in three cases of
DLBCL, two cases of PTCL-NOS and one case of
EATL, representative of the spectrum of frequency
and intensity of staining. All participants of round 1
were present in scoring round 2. This was followed
by a presentation on the pitfalls of CD30 IHC inter-
pretation by one of the authors (L.K.), after which
exactly the same scoring procedure was directly
repeated. The pitfalls discussed comprised CD30-posi-
tivity in reactive cells, technical issues and the inter-
pretation of cases with tumour cells that show the
same size as reactive surrounding cells.
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Round 3 consisted of 20 cases presented as repre-
sentative photographs of the haematoxylin and eosin
(H&E)-stained slides, CD30 IHC and relevant diagnos-
tic IHC markers. Participants, who had all attended
the national workshop, scored the CD30 IHC stain in
a series consisting of representative areas of 13 cases
of DLBCL, two cases of PTL-NOS, two cases of EATL,
one case of ALK1-negative ALCL and one case of
extranodal NK/T cell lymphoma, nasal type. All cases
were revised beforehand (L.K., D.J.), according to the
latest criteria.
S T A T I S T I C A L A N A L Y S I S
Inter-rater agreement was quantified by means of
kappa coefficients and percentage of pairs in agree-
ment. Overall kappa coefficients for exact agreement
and multiple raters were calculated in STATA version
1414 for percentage positivity and intensity. Confi-
dence intervals were obtained using a bootstrap pro-
cedure. Percentage agreement and two-rater kappa
coefficients were calculated in R version 2.3.515 for
each pair of raters. The average kappa and average
percentage agreement were calculated together with
their range to show the variability in agreement
between different pairs of raters. Kappa coefficients
and percentage agreement for percentage positivity
allowing for one category of freedom were calculated
in R for each pair of raters. The average of the kappa
coefficients and their range were calculated. Finally,
kappa coefficients and percentage agreement were
calculated for positivity using fictional cut-off points
of 2 and 10%. We categorised kappas as poor
(< 0.40), fair (0.40–0.75) or excellent (> 0.75).
Results
An overview of the results of the three scoring rounds
is represented in Table 1.
R O U N D 1
IHC for CD30 on a TMA containing 20 lymphoma
cases and two staining control tissues was performed
in five pathology laboratories according to routine
procedures using automated staining protocols [Dako
Autostainer platform n = 2 (Dako, Glostrup, Den-
mark), Ventana Medical Systems Benchmark platform
n = 3 (Ventana Medical Systems, Oro Valley, AZ,
USA)] and anti-CD30 antibody clone Ber-H2 [Ven-
tana Ber-H2 (790-4858) n = 3, Dako Ber-H2 (IR602)
n = 1, Dako Ber-H2 (M0751) n = 1)]. Slides were
scored according to local guidelines. Despite the use
of the same antibody clone, the staining results varied
dramatically (Figure 1), resulting in pairwise agree-
ment of 46% and a j of 0.35 for percentage of posi-
tive tumour cells and pairwise agreement of 56% and
a j of 0.47 for staining intensity. Overall, there was
a minor difference in agreement between the patholo-
gists scoring slides stained in the Dako automated
platform (percentage positivity; pairwise agreement
56%/j = 0.46 and intensity; pairwise agreement
83%/j = 0.79) and those scoring the Ventana plat-
form stained slides (percentage positivity; pairwise
agreement 42%/j = 0.31 and intensity; pairwise
agreement 49%/j = 0.39). Different laboratory tech-
niques could not explain the staining and scoring
results systematically.
R O U N D 2
In round 2, pilot scoring of CD30 was performed as
‘real-life validation’ using a live polling system with
22 medical professionals. Based on six cases, agree-
ment for all participants was poor both for quantita-
tive results (pairwise agreement 33%/j = 0.17) and
for assessment of staining intensity (pairwise agree-
ment 53%/j = 0.36). Reproducibility was still poor
when allowing for one category of freedom in the
CD30 tumour cell positivity class [overall pairwise
agreement 63%/j = 0.33, for (haemato)pathologists
pairwise agreement 62%/j = 0.30]. The same slides
were rescored after a presentation on pitfalls (L.K.),
with 17 medical doctors of the first scoring round
participating. Sixteen of the 17 participants changed
their scores for one to five cases (mean 2.9 cases
changed), with one or more categories in either direc-
tion or not scoring at all (Figure 2). Fourteen of the
17 participants changed their interpretation of stain-
ing intensity in one to six cases, but with a substan-
tially lower mean of 1.8 cases changed. Overall, the
changes in interpretation between the two rounds
before and after instruction resulted in similar subop-
timal agreement scores.
R O U N D 3
Round 3 was designed to mimic a true diagnostic sit-
uation. Information on classifying lymphoma diagno-
sis and scanned images of H&E-stained slides and
relevant IHC as support for recognition of tumour
cells (CD20, CD3) were provided. All cases were
scored by 15 participants, including five academic
haematopathologists, six pathologists with a special
interest in haematopathology and four residents with
© 2018 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 73, 473–482.
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































© 2018 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 73, 473–482.
476 L Koens et al.
basic training in haematopathology. The distribution
of percentage classes of CD30-positivity per tumour
varied substantially among the individual partici-
pants, showing that some pathologists have a system-
atic tendency for higher scores of CD30-positivity
than others (Figure 3). Exact pairwise agreement in
CD30-positive tumour cell percentage and staining
intensity were 33% (j = 0.20) and 74% (j = 0.36),
respectively, and therefore no substantial improve-
ment from round 2 was reached. In contrast to scor-
ing round 2, allowing for one category of freedom in
CD30-positive tumour cell percentage led to an
improvement of reproducibility to fair agreement
(pairwise agreement 71%/j = 0.50). Agreement
levels were not dependent upon the level of training
or experience in years of practice of the participants.
Using fictional cut-points of 2 and 10% positivity,
fair agreement was reached (2% cut-off: pairwise
agreement 78%/j = 0.48; 10% cut-off: pairwise
agreement 76%/j = 0.52) (Table 2). A 2% cut-point
classified five of 20 cases as positive by all partici-
pants, whereas for the 10% cut-off six of 20 cases
were scored with complete agreement (three cases
CD30-negative and three cases CD30-positive). For
implementation of CD30 scoring as a tool for treat-
ment decisions, discordant decisions around the cut
off-points are most relevant. Using dichotomised cut-
points for (virtual) trial inclusion, opinion on inclu-
sion or not differed from the majority opinion in up
to 46% of the pathologists (mean 2.15 participants
for the 2% cut-point, mean 2.25 for the 10% cut-
point). As an example, in case 15, 11 of 15 patholo-
gists considered the tumour CD30-positive using a
2% cut-point and four of 15 pathologists considered
the tumour CD30-positive with a 10% cut-point (Fig-
ure 4), emphasising the ambiguity in interpretation,
especially in tumours with relatively few CD30-posi-
tive tumour cells.
Discussion
Biomarker assays as a selection tool for treatment
with targeted compounds should be technically
A B C
D E F
Figure 1. CD30 immunohistochemistry performed on tissue microarrays (TMA) in five different laboratories. An overview of the different
CD30 immunohistochemistry slides shows apparent differences in staining intensity in some of the cores. A, B, Stained by the Ventana
Benchmark stainer with a Ventana Ber-H2 antibody; C, stained by the same machine, but with a Dako Ber-H2 antibody; D, E,) stained by
the Dako Autostainer, using a Dako Ber-H2 antibody.
© 2018 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 73, 473–482.
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robust and interpretation should be reproducible. In
this study, we show that the results for CD30 stain-
ing on FFPE biopsy samples of malignant lymphomas
are variable between five laboratories, in which this
procedure is part of routine lymphoma work-up.
Although all results were fully adequate for diagnos-
tic classification purposes, this variation resulted in
major differences in quantitative and qualitative
assessment of CD30 data. These results are in line
with a quality monitoring study by NordiQC, showing
that only 179 of 252 (71%) of laboratories tested
were able to produce an optimal CD30 staining
according to well-described criteria, supporting the
notion that staining heterogeneity is a factor that
cannot be ignored in the broader pathology commu-
nity.13 Technical variation for IHC and its impact on
standardisation of biomarker scoring has also been
demonstrated for other membranous, cytoplasmic
and nuclear markers in lymphoma.16 As a conse-
quence, we still advise central processing of biopsy
samples for treatment selection in the context of clini-
cal trials, including those employing CD30-targeting
drugs. However, as tissue fixation and subsequent tis-
sue processing protocols inevitably vary considerably
between laboratories, at least some variation will
remain inherent to IHC-based assays. It will not be
possible to define universally optimised staining pro-
cedures as a gold standard for determining CD30-
positive tumour cell percentage and intensity.
Variation in CD30-positive tumour cell percentage
scoring and intensity assessment cannot only be
explained by technical differences between laborato-
ries. Also, when assessing CD30-positive tumour cell
percentage and intensity from the same digitalised
slides and under the same circumstances, agreement
between pathologists is still poor to fair, at best. The
difficulty in decision-making was emphasised by the
high percentage of participants who showed a high
level of intraobserver variability when scoring the
same cases twice at the ‘real-time validation’ effort.
Indeed, even experienced haematopathologists in this
group were hesitant to provide their scores in the sec-
ond round after a presentation on pitfalls in interpre-
tation. These results highlight that the same slides
can be interpreted in different ways, even by the
same pathologist, and interpretation can be influ-
enced by the mention of potential pitfalls. A possible
weakness of this ‘real-life validation’ effort is the
































Case 4 Case 5 Case 6
Figure 2. Intra-observer variation in the interpretation of percentage tumour cell positivity. In round 2, a substantial number of the partici-
pants changed their opinion on the percentage of tumour cell positivity for the same slide only 15 min after scoring it for the first time,
sometimes even changing several scoring categories.
© 2018 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 73, 473–482.
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somewhat artificial setup. In daily practice, IHC stains
are never assessed outside their context of clinical
information, morphology and a panel of diagnostic
immunohistochemical stains to provide information
on architectural distribution and cellular properties of
tumour cells and reactive cell populations. Therefore,
in the third validation round, H&E slides and essential
additional images of diagnostic IHC slides were pro-
vided to mimic a real-life situation. The agreement
did not improve substantially, however. Although the
exact agreement in quantifying CD30-positive neo-
plastic cells was still suboptimal, allowing for one cat-
egory of freedom in this category improved
agreement substantially to fair.
Our study showed that quantifying CD30-positive
tumour cells is variable among pathologists. This phe-
nomenon may not pose excessive problems for the
























Figure 3. The distribution of scoring CD30 tumour cell positivity percentage. For scoring round 3, the results per individual participants are
depicted, emphasising individual variation and the tendency of some participants to easily score higher tumour cell positivity than others.
Table 2. Pairwise agreement and j using cut-off values for percentage of tumor cell positivity
n
> 2% tumour positivity >10% tumour positivity
% agreement j % agreement j
Round 3 overall 15 78 0.49 (0.29, 0.69) 76 0.51 (0.33, 0.70)
Pathologist 11 80 0.49 (0.27, 0.71) 78 0.54 (0.34, 0.74)
Academic pathologist 5 85 0.57 (0.30, 0.85) 82 0.60 (0.35, 0.85)
Non-academic pathologist 6 76 0.35 (0.14, 0.56) 73 0.45 (0.24, 0.66)
Resident 4 71 0.43 (0.15, 0.70) 75 0.45 (0.12, 0.77)
© 2018 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 73, 473–482.
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based on a dichotomised score, as these currently
include classes that are uniformly CD30-positive
[ALCL; uniform CD30-positivity in 100%, and classi-
cal Hodgkin lymphoma; uniform CD30-positivity in
100% and DLBCL, uniform CD30-positivity in 19% in
the relapse setting (based on the files of the Amster-
dam Comprehensive Cancer Center Database, D. de
Jong, personal communication)]. For heterogeneously
CD30-positive lymphoma classes that are increasingly
considered for targeted treatment, the situation may
be more challenging.
One of the alternatives to improve reproducibility
of CD30 assessment as a treatment selection tool may
be automated image analysis-based scoring. In a
Phase II study of brentuximab vedotin in relapsed/re-
fractory DLBCL with variable CD30 expression, all
responding patients had quantifiable CD30 by com-
puter-assisted assessment of IHC,8 albeit that there
was no statistical correlation between response and
level of CD30 expression. Staining intensity of CD30
was not considered in this study. However, interpre-
tation of IHC stainings, irrespective of conventional
‘manual’ assessment or computer-assisted scoring, is
complicated by the difficult differentiation of CD30
staining in neoplastic cells versus non-malignant
CD30-positive cells in the tumour microenvironment,
such as various populations of resting CD8-positive T
cells, activated T cells, activated reactive B cells and
NK cells.17 In particular, if the cut-off point for CD30-
positivity for study eligibility is set at a very low per-
centage, such as 1 or 2%, reactive CD30-positive cells
may easily influence decision-making. In a study in
PTCL, CD30 IHC was shown to be correlated highly
with mRNA levels using an IHC scoring system incor-
porating both staining intensity and percentage of
positive tumour cells.18 However, measurement of
CD30 mRNA as an alternative assay may be techni-
cally more complicated and expensive and, also using
this technique, CD30-positive tumour cells cannot be
distinguished from CD30-positive surrounding reac-
tive cells. Flow cytometry [fluorescence activated cell
sorter (FACS) analysis] has the advantage of a quan-
titative assay, allows for multiple-marker staining and
is often more sensitive than IHC. However, fresh tis-
sue suspensions, necessary for this technique, are not
always available and the cell membrane of the large
tumour cells of CD30-positive T and B cell lym-
phomas is often vulnerable and easily shed when
preparing cell suspensions for FACS, precluding use
in daily practice.19 Another way to evaluate CD30 is
the detection of soluble CD30 in peripheral blood. Sol-
uble CD30 is the extracellular domain of CD30 that is
released into the circulation after proteolytic cleavage
near the cell membrane, and can be detected by
enzyme-linked immunosorbent assay (ELISA).20 Sol-
uble CD30 levels have been shown to be correlated
A B
C D
Figure 4. Case example. This case shows the pictures that were evaluated and scored by the participants of a diffuse large B cell lymphoma
with CD30 (A), haematoxylin and eosin (B), CD20 (C) and CD3 (D), showing considerable variation in assessment, especially using the fic-
tional 2% and 10% cut-off for CD30 positivity.
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with disease burden in ALCL,21 clinical features and
prognosis in CHL,22 but the levels of soluble CD30
are not correlated with clinical response to brentux-
imab vedotin in relapsed/refractory DLBCL.8 These
alternative methods for CD30 quantification therefore
all seem to have more disadvantages than benefits,
and conventional visual scoring of CD30 IHC by
pathologists thus remains an important method to be
optimised.
The role of staining intensity of CD30 in the clin-
ical response to treatment with brentuximab vedo-
tin is unclear. The only study correlating CD30
expression with this response did not consider stain-
ing intensity.8 The study showing high correlation
between CD30 IHC and CD30 mRNA levels18 con-
sidered both staining intensity and percentage of
positive tumour cells, indicating that staining inten-
sity might be extremely relevant in assessing this
marker. This study was, however, restricted to
peripheral T cell lymphomas, and there is no evi-
dence that this type of CD30 IHC scoring or mRNA
expression are correlated with clinical response to
brentuximab vedotin.
In summary, reproducibility of the IHC CD30 stain
is suboptimal, in part by variation in staining meth-
ods and patterns between different pathology labora-
tories, but due also to interobserver variation
between pathologists. These differences could poten-
tially influence patient eligibility for clinical trials
with antibody-drug conjugate brentuximab vedotin,
and also hamper the correlation of the amount of
CD30-positive neoplastic cells to the degree of clinical
response to this treatment.
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